Protara Therapeutics Inc (FRA:1KPA)
€ 1.51 -0.01 (-0.66%) Market Cap: 32.23 Mil Enterprise Value: -44.61 Mil PE Ratio: 0 PB Ratio: 0.39 GF Score: 39/100

Protara Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 14, 2023 / 05:20PM GMT
Release Date Price: €2.56 (-13.51%)
Leland Gershell
Oppenheimer & Co. Inc. - Analyst

Thanks. Good afternoon, everyone. Welcome back to another session here at Oppenheimer's 33rd Annual Healthcare Conference. I'm Leland Gershell, one of the analysts on the biotech equity research team, and very delighted to have with us Protara Therapeutics as our next presenting company.

If you've been following our research, you know that we like the TARA story very much and, on behalf of Protara, we have the company's CEO, Jesse Shefferman, who will walk through the story. We will have some time for Q&A at the end, so please submit any questions you have through Zoom or you can e-mail me at [email protected]. And with that, I'll hand it over to Jesse.

Jesse Shefferman
Protara Therapeutics, Inc. - Co-founder, Director, CEO

All right. Thanks, Leland and the whole Oppenheimer team for having us here. On our next slide, we have a brief pause on standard disclaimers, which we're just actually just going to get through. Protara is a New York-based biotech. We're focused on oncology and rare

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot